Atralin Gel for the Treatment of Rosacea

Exclusion Criteria

• •1. Severe self reported facial sensitivity
• •2. History of allergy to fish
• •3. Severe sun sensitivity
• •4. Severe erythematotelangiectatic rosacea requiring systemic treatment
• •5. Papulopustular, Ocular-only, Phymatous rosacea, Steroid rosacea, pyoderma faciale
• •6. Unwilling to undergo facial biopsies
• •7. Concomitant use of medications that are reported to exacerbate rosacea, such as topical and systemic steroids
• •8. Use of topical rosacea treatments in the past 2 weeks.
• •9. Use of systemic antibiotics in the past 4 weeks.
• •10. Use of systemic retinoids within the past 6 months.
• •11. Use of topical retinoids within the past 3 months
• •12. Use of laser or light based rosacea treatments within the past 2 months.
• •13. Cosmetic procedures (e.g., superficial chemical peels, exfoliation or microdermabrasion of the face) within the past two months
• •14. Use of topical anti-aging medications including alpha hydroxy acids, salicylic acid, beta-hydroxy acid, vitamin A, vitamin E, ascorbic acid
• •15. Other dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments.
• •16. Clinically significant abnormal findings or conditions (other than rosacea), which might, in the opinion of the Investigator, interfere with study evaluations or pose a risk to subject safety during the study.
• •17. If female, Subjects who are either of non-child bearing potential (defined as postmenopausal -absence of menstrual bleeding for 1 year - or as having undergone bilateral tubal ligation, hysterectomy or bilateral ovariectomy) or, if of childbearing potential, Subjects who have had a negative urine pregnancy test at the beginning of the study, and have agreed to practice appropriate birth-control to prevent pregnancy during the study.(The type and dose of birth control must have been stable for at least 2 months prior to study entry and not be expected to change during the study).
• •18. Subjects who are lactating.
• •19. Use of any investigational therapy within the past 4 weeks.
• •20. Known hypersensitivity or previous allergic reaction to retinoids
• •21. Carcinoid, Pheochromocytoma or other systemic flushing causes